These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28364669)

  • 1. Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea.
    Ryu JM; Kang G; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Kim JW; Park SS; Lee JE; Kim SW
    Breast; 2017 Jun; 33():109-116. PubMed ID: 28364669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant.
    Park HS; Ryu JM; Park JS; Im SA; Jung SY; Kim EK; Park WC; Min JW; Lee J; You JY; Lee JE; Kim SW
    Cancer Res Treat; 2020 Jul; 52(3):680-688. PubMed ID: 32019279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically Significant Unclassified Variants in
    Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
    Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
    Spurdle AB; Whiley PJ; Thompson B; Feng B; Healey S; Brown MA; Pettigrew C; ; Van Asperen CJ; Ausems MG; Kattentidt-Mouravieva AA; van den Ouweland AM; ; Lindblom A; Pigg MH; Schmutzler RK; Engel C; Meindl A; ; Caputo S; Sinilnikova OM; Lidereau R; ; Couch FJ; Guidugli L; Hansen Tv; Thomassen M; Eccles DM; Tucker K; Benitez J; Domchek SM; Toland AE; Van Rensburg EJ; Wappenschmidt B; Borg Å; Vreeswijk MP; Goldgar DE;
    J Med Genet; 2012 Aug; 49(8):525-32. PubMed ID: 22889855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer.
    Lee JD; Ryu WJ; Han HJ; Kim TY; Kim MH; Sohn J
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
    Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
    Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new bioinformatics tool to help assess the significance of BRCA1 variants.
    Cusin I; Teixeira D; Zahn-Zabal M; Rech de Laval V; Gleizes A; Viassolo V; Chappuis PO; Hutter P; Bairoch A; Gaudet P
    Hum Genomics; 2018 Jul; 12(1):36. PubMed ID: 29996917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
    Zuntini R; Cortesi L; Calistri D; Pippucci T; Martelli PL; Casadio R; Capizzi E; Santini D; Miccoli S; Medici V; Danesi R; Marchi I; Zampiga V; Fiorentino M; Ferrari S; Turchetti D
    Oncotarget; 2017 Apr; 8(14):22640-22648. PubMed ID: 28186987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
    Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
    Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
    Kluska A; Balabas A; Paziewska A; Kulecka M; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2015 May; 8():19. PubMed ID: 25948282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Tudini E; Moghadasi S; Parsons MT; van der Kolk L; van den Ouweland AMW; Niederacher D; Feliubadaló L; Wappenschmidt B; Spurdle AB; Lazaro C
    Breast Cancer Res Treat; 2018 Nov; 172(2):497-503. PubMed ID: 30105462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
    Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
    Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.
    Park JS; Nam EJ; Park HS; Han JW; Lee JY; Kim J; Kim TI; Lee ST
    Cancer Res Treat; 2017 Oct; 49(4):1012-1021. PubMed ID: 28111427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
    Dobricić J; Branković-Magić M; Filipović S; Radulović S
    Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.